The Food and Drug Administration (FDA) has sanctioned labeling for physIQ's continuous remote monitoring system, pinpointIQ, for use with the COVID-19 pandemic. The labeling includes the use of the physIQ's multivariate change index (MCI). The remote monitoring system will provide continuous remote monitoring for confirmed or suspected COVID-19 patients or high-risk patients such as those with heart failure or hypertension. The system will passively collect wearable sensor data and apply advanced analytics to help health care facilities and lower the risk of exposure for patients and health care providers. 

With 12 documents in the AI Biotech/Diagnostics sector (4 documents directed towards "multivariate residual-based health index for human health monitoring"), physIQ shows dedication to enabling proactive care delivery models through personalized physiology analytics. Hopefully, the data and analysis provided from physIQ's platform will offer healthcare providers with an improved understanding of the COVID-19 pandemic.